Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus POLYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus POLYMOX.
PENICILLIN-2 vs POLYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic